1. Home
  2. CCEP vs NTRA Comparison

CCEP vs NTRA Comparison

Compare CCEP & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coca-Cola Europacific Partners plc

CCEP

Coca-Cola Europacific Partners plc

N/A

Current Price

$100.71

Market Cap

44.4B

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$410.26

Market Cap

47.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CCEP
NTRA
Founded
1986
2003
Country
United Kingdom
United States
Employees
41000
N/A
Industry
Beverages (Production/Distribution)
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.4B
47.4B
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
CCEP
NTRA
Price
$100.71
$410.26
Analyst Decision
Buy
Strong Buy
Analyst Count
13
24
Target Price
$109.20
★ $352.80
AVG Volume (30 Days)
★ 1.4M
1.2M
Earning Date
08-04-2026
11-05-2026
Dividend Yield
★ 2.35%
N/A
EPS Growth
N/A
★ 0.65
EPS
★ N/A
N/A
Revenue
N/A
★ $210,939,000.00
Revenue This Year
$3.29
$26.17
Revenue Next Year
$3.86
$20.40
P/E Ratio
$20.93
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$84.66
$160.59
52 Week High
$113.67
$421.64

Technical Indicators

Market Signals
Indicator
CCEP
NTRA
Relative Strength Index (RSI) 41.59 83.00
Support Level $99.00 $187.64
Resistance Level $109.54 N/A
Average True Range (ATR) 1.74 13.91
MACD 0.05 3.74
Stochastic Oscillator 27.58 88.66

Price Performance

Historical Comparison
CCEP
NTRA

About CCEP Coca-Cola Europacific Partners plc

CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: